Pfizer’s Xalkori Extends Lung Cancer Patient Survival

Pfizer yesterday revealed information that demonstrates that Xalkori considerably improved progression-free survival in previously-treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Xalkori (crizotinib) gained approval by the US Food and Drug Administration (FDA) in August 2011 for ALK-positive advanced NSCLC, but Pfizer points out that this latest clinical study, Profile

Continue Reading

NHS Public Satisfaction Rates Tumble

Public satisfaction regarding how the NHS functions across the UK dropped by 12% last year, to 58% from 70% in 2010, according to the most recent British Social Attitudes Survey. This is the largest decrease in one year from when the survey started in 1983, although it still remains the third highest documented level of

Continue Reading

Study Finds European Healthcare

In spite of the financial crisis, healthcare across Europe continues to improve, with consumer empowerment motivating advances in quality and access. However, the distribution of cancer drugs within the UK is still “deplorable,” states a new review, presented at the European Parliament in Brussels. The Netherlands appears first in the latest Euro Health Consumer Index

Continue Reading

Patient Support Programmes Create Better Result

Patient support programmes (PSP) which involve patients paying part of the fee for their prescription drugs, provide better outcomes than programmes that allow patients to obtain their medication entirely free, eyeforpharma’s Patient Summit conference heard. Patient support programmes offer some monetary support, plus nursing support, and requires patients to pay some additional drug costs to

Continue Reading

Teva Reduces 2012 Profit Forecasts

Teva Pharmaceuticals yesterday announced that they have reduced their sales and earnings predictions for 2012 partly as a result of pricing problems and currency effects in Europe. The organisation is now forecasting earnings in the range of $5.30-$5.40 per share, down from prior guidance of $5.48-$5.68.  Turnover is expected to reach $20-$21 billion, down from

Continue Reading

Essential Drugs Unavailable as Greek Pharmacists Strike

Approximately 163 critical drugs are now unobtainable from pharmacies in Greece, sector leaders stated, in advance of the country’s pharmacists’ planned one-day strike today. Drugstores in Greece are closed today as owners demonstrate against the fact that social security funds are yet to pay their growing unpaid medication bill. Pharmacists have decided to shut their

Continue Reading

Auranofin ‘Promising’ to Treat Amoebic Dysentery

Auranofin, a common and cheap drug currently used for arthritis, could help fight against parasitic organisms responsible for amoebic dysentery, according to US researchers. Amoebic dysentery is caused by Entamoeba histolytica, which infects the bowels.  It results in severe diarrhoea as well as bloody stools.  More than 70,000 people globally are believed to die from

Continue Reading